Table 4.
Factors associated with the presence of pain at the 3-month evaluation of COVID-19 patients
| Variable | Patients with pain in the third month |
Patients without pain in the third month |
p a) | ||
|---|---|---|---|---|---|
| Male | Female | Male | Female | ||
| Age (y) | 53.4±12.7 | 53.1±9.5 | 54.7±13.5 | 52.1±13.8 | 0.727 |
| p | 0.897 | 0.443 | |||
| Comorbidity | |||||
| Yes | 0.238 | 0.762 | 0.521 | 0.479 | 0.248 |
| No | 0.5 | 0.5 | 0.64 | 0.36 | |
| p | 0.215 | 0.330 | |||
| VAS (initial) | 69.3±12.9 | 72.8±12.7 | 15.7±27.6 | 16.7±30.1 | <0.001 |
| p | 0.938 | 0.966 | |||
| FSS (3 mo) | 3.9±1.4 | 3.5±1.7 | 2.0±1.7 | 2.2±1.3 | <0.001 |
| p | 0.559 | 0.376 | |||
| HADS-anxiety (3 mo) | 4.1±4.8 | 2.6±2.4 | 2.1±3.7 | 2.8±4.4 | 0.034 |
| p | 0.658 | 0.596 | |||
| HADS-depression (3 mo) | 6.8±8.2 | 2.6±1.9 | 2.1±4.4 | 2.3±4.4 | 0.002 |
| p | 0.585 | 0.753 | |||
Data are presented as mean±standard deviation.
COVID-19, coronavirus disease 2019; VAS, visual analog scale for measuring pain; FSS, fatigue severity scale; HADS, hospital anxiety depression scale.
a)
Significance value of the parameters compared without male-female grouping between patients with and without pain at the third month.